The fourth edition of the Dutch ATMP Summit is organized around the theme of Automation in ATMP manufacturing
March 12 2025, Corpus Leiden
Shape the Future of ATMP Manufacturing: Join the Dutch ATMP Summit 2025 in Corpus Leiden
Get ready to dive into the future of ATMP production at the Dutch ATMP Summit 2025! This year, we’re focusing on Automation in ATMP Manufacturing, and how it’s revolutionizing the field.
Automation is not just a trend—it’s transforming the production of Advanced Therapy Medicinal Products (ATMPs), driving efficiency, reducing errors, and scaling operations like never before. Industry leaders will share real-world insights on how they’re implementing cutting-edge technologies to reshape manufacturing processes.
Join top experts as they deliver impactful presentations, revealing the latest advancements in automation and their game-changing potential for healthcare. You’ll also have the chance to tackle automation challenges head-on during our dynamic Q&A sessions, where thought leaders will offer clear strategies to integrate these innovations seamlessly into your production systems.
This is your opportunity to stay ahead of the curve in the rapidly evolving ATMP sector. Plus, with unparalleled networking opportunities, you’ll connect with key players, exchange ideas, and ignite new collaborations that could shape the future of your business.
Don’t miss out and mark your calendar for March 12, 2025, and be part of the transformation at Corpus Leiden!
Shape the Future of ATMP Manufacturing: Join the Dutch ATMP Summit 2025 in Corpus Leiden
Get ready to dive into the future of ATMP production at the Dutch ATMP Summit 2025! This year, we’re focusing on Automation in ATMP Manufacturing, and how it’s revolutionizing the field.
Automation is not just a trend—it’s transforming the production of Advanced Therapy Medicinal Products (ATMPs), driving efficiency, reducing errors, and scaling operations like never before. Industry leaders will share real-world insights on how they’re implementing cutting-edge technologies to reshape manufacturing processes.
Join top experts as they deliver impactful presentations, revealing the latest advancements in automation and their game-changing potential for healthcare. You’ll also have the chance to tackle automation challenges head-on during our dynamic Q&A sessions, where thought leaders will offer clear strategies to integrate these innovations seamlessly into your production systems.
This is your opportunity to stay ahead of the curve in the rapidly evolving ATMP sector. Plus, with unparalleled networking opportunities, you’ll connect with key players, exchange ideas, and ignite new collaborations that could shape the future of your business.
Don’t miss out and mark your calendar for March 12, 2025, and be part of the transformation at Corpus Leiden!
Full day program
08:30 – 09:00 Registration & walk-in
We will start the program with a cup of coffee and some snacks
09:00 – 09:15 Opening
After a warm welcome from our CCO Edwin van den Bos, the host of the day, Cor Marsman, will kick-off the program
09:15 – 10:45
- Thijs Booiman – Senior Consultant at Progress – Experts in Life Sciences: “Review of the Market on QC Automation in ATMP Manufacturing”
- Marieke Klijn – Assistant Professor Data-Driven Bioprocess Development at TU Delft and Ramon van Valderen PhD candidate, CFD modelling for ATMP scale-up: “Accelerating ATMP process development: in-line analytics and CFD simulations”
10:45 – 11:15 Coffee break & networking
Enjoy some coffee and refreshments and get ready for the next presentation
11:15 – 12:00 presentation
- Mark Duerkop – CEO of novasign and Evan Claes – Control Architect at Antleron: “Digital-Twin assisted Biomanufacturing: From accelerated Process Development to automated Process Control”
12:00 – 13:00 Lunch & networking
Enjoy a well prepared lunch and get ready for the next part of the Dutch ATMP Summit
13:00-13:15 Energizer
Regain your energy after the lunch
13:15 – 14:45 Presentations
- Janet Hoogstraate – CEO NorthX Sweden: “How to set-up the GMP production of a cell therapy for Acute Myeloid Leukemia (AML) including automation in manufacturing, QC & release testing”
- Marc Kamp – Director Quality Engineering and Program Lead GxP Quality Cell Therapy at Kite: “Implementation of automation in CAR T cell therapy production”
14:45 – 15:15 Coffee break & networking
Enjoy some coffee and refreshments and get ready for the final presentation and Q&A session
15:15 – 16:00 Presentation
- Jacek Lubelski – CTO Nanocell Therapeutics: “Transforming cell & gene therapy”
16:00 – 16:30 Q&A session and round-up of the Dutch ATMP Summit
Ask the speakers of the Dutch ATMP Summit questions you still have
16:30 – 17:30 Networking drinks session
Enjoy some drinks, snacks & the full opportunity to networka
Speakers
Dr. Thijs Booiman
Senior Consultant
Progress Experts in Life Sciences
Thijs Booiman started working at Progress in May 2023. He obtained his PhD in virology and immunology at the University of Amsterdam. After completing his post-doctoral research he worked for Eurofins MicroSafe in the role of study manager and department head. There he was responsible for the tech transfer and validation of various quality control methods for the testing of biologicals. After Eurofins he worked at HALIX as a project manager responsible for the tech transfer, development and manufacturing of several antibodies and viral vectors. In 2021 he moved to NecstGen as lead scientist quality control for ATMPs. In this role he was responsible for setting up the quality control department, LIMS implementation, clean room PQ execution and the implementation of microbial and rapid qc methods.
Dr. Mark Duerkop
Chief Executive Officer
novasign
With more than 15 years of experience, Mark is a passionate expert in biopharmaceutical process development. He worked together with several Pharma companies in different projects, targeting their process development and understanding needs. After finishing his PhD in the Field of Bioprocess Development in the laboratory of Alois Jungbauer, Mark decided to found a company focusing on the field of bioprocess modeling. Leading Novasign as CEO, Mark and his team develop a hybrid modeling software for both up and downstream processes. This software utilizes AI applied to process data and first-principle models (hybrid models) to faster and better predict critical quality attributes (CQAs) from critical process parameters (CPPs). Hereby, bioprocess development and characterization are accelerated significantly while a better process understanding is gathered. The company Novasign was founded in 2019 offering this unique software solution which is already in use by several TOP25 pharma companies to also accelerate their process development.
Evan Claes MSc
ATMP Monitoring &
Control Architect at Antleron
Evan has close to a decade of experience in the ATMP sector, specializing in innovative approaches to process monitoring and optimization. His work involves soft sensing and hybrid process modelling, supporting the development of scalable and sustainable biomanufacturing solutions. Most of this work was done at Antleron, a company operating at the intersection of life sciences and digital technologies, offering personalized and digitalized manufacturing solutions for advanced therapies. Based in Leuven, the company has been an important contributor to Europe’s thriving biotech ecosystem for 10 years. With its state-of-the-art facilities, multidisciplinary team, and focus on innovative R&D, Antleron provides transformative technology solutions that enable affordable, scalable, and customized bioprocesses for advanced therapies.
Dr. Janet Hoogstraate
Chief Executive Officer
NorthX Biologics
Janet Hoogstraate is CEO of NorthX Biologics AB since September 2023. She has a PhD in Bio-Pharmaceutical Sciences from Leiden University, did academic research at the University of Utah and University of Iowa. She has an executive MBA from Hult International business school in London.
Janet has worked over 25 years in the pharmaceutical industry with various leadership roles at AstraZeneca working in neuroscience and pain, followed by setting up a Science Park at Acturum Life Sciences and leading a commercial and clinical vaccine manufacturing site as Managing Director at Valneva Sweden. Janet is a board member of 3 European life science companies. Today, she works at NorthX Biologics, a Swedish national innovation hub and CDMO for advanced biologics in Sweden.
Dr. ir. Marieke Klijn
Assistant Professor Data-Driven Bioprocess Development at Technische Universiteit Delft
After a MSc in Biochemical Engineering and a PhD in protein analytics and machine learning, Marieke established a research group in 2020 at Delft University of Technology with a focus on applying advanced analytics to understand, develop, and control bioprocesses. The topics in her research group range from microbial fermentation to ATMP production, where synergy is found in the application of in-line analytics, development of technology to speed up data-driven modelling, and work towards data-driven control strategies.
Ramon van Valderen MSc
scale-up at Technische Universiteit Delft
Ramon obtained his MSc in Biochemical Engineering at Delft University of Technology, with a specific focus on mathematical modelling and machine learning. After that, he continued in Delft for a PhD in the department of Bioprocessing, where he is currently focused on using Computational Fluid Dynamics (CFD) models for upscaling cell culture processes in bioreactors.
Dr. Marc Kamp
Kite, a Gilead company
Details will follow soon.
Jacek Lubelski, PhD, MBA
Chief Technology Officer
NanoCell Therapeutics
Mr. Lubelski is an accomplished biopharmaceutical leader, researcher and pharmaceutical developer specializing in gene and cell therapy and viral vector production. With over a decade-long career, he has made significant contributions to the development and advancement of gene therapy technologies, particularly in the field of recombinant adeno-associated virus (rAAV) therapeutics.
Prior to joining NanoCell Therapeutics, Mr. Lubelski served as the VP of Pharmaceutical Development at UniQure NV (NASDAQ: QURE). He has contributed to obtaining market authorization for Glybera, the first approved gene therapy medicine in the Western World, to treat lipoprotein lipase ( LPL) deficiency and market authorization of Hemgenix to treat Haemophilia B. He has been instrumental in developing multiple rAAV-based translational advanced therapy medicinal products (ATMPs) to address challenging diseases like Haemophilia B, Sanphilipo B, and Acute Intermittent Porfyria. As Vice President of Development, Mr. Lubelski also led vector process and analytical development as well as , pre-clinical studies, and CMC activities focused on rAAV-based therapies. His expertise in leading complex teams across Europe and the USA has resulted in successful design and implementation of technological processes and analytical methods for viral vector manufacturing platforms.
In his current role as the Chief Technology Officer at NanoCell Therapeutics, Mr. Lubelski spearheads all research and development activities. Dr. Lubelski was also selected as an expert by the European Directorate for the Quality of Medicines & Healthcare (EDQM) He has coauthored more then 20 scientific publications as well as multiple patent applications pertaining to gene therapy filed.
Mr. Lubelski holds a Ph.D. in Molecular Microbiology from the University of Groningen, a Master's degree in Biotechnology from Maria Curie-Sklodowska University in Lublin, Poland and an MBA degree from the Rotterdam School of Management, Erasmus University in Rotterdam, the Netherlands.
Speakers
Dr. Thijs Booiman
Senior Consultant at Progress – Experts in Life Sciences
Dr. Mark Duerkop
CEO at novasign
Evan Claes MSc
ATMP Monitoring & Control Architect
Dr. ir. Marieke Klijn
Assistant Professor Data-Driven Bioprocess Development at Technische Universiteit Delft
Ramon van Valderen MSc
PhD candidate, CFD modelling for ATMP scale-up at Technische Universiteit Delft
Dr. Janet Hoogstraate
CEO at NorthX Biologics Sweden
Dr. Marc Kamp
Director Quality Engineering and
Program Lead GxP Quality Cell Therapy
Dr. Jacek Lubelski
CTO at NanoCell Therapeutics
Dutch ATMP Summit 2025
With this ticket you will get access the the Dutch ATMP Summit on Wednesday, March 12, 2025 in, Corpus Leiden. You can join all the talks of our speakers and meet your colleagues in the field during networking drinks. During the day there are refreshments.
Second ticket for half of the price.
Presentations
Review of the Market on QC Automation in ATMP Manufacturing
Dr. Thijs Booiman - Progress - Experts in Life Sciences
Over the past 25 years, Progress – Experts in Life Sciences has partnered with many clients to design, build, and/or operationally release pharmaceutical facilities, both for bulk non-ATMPs as well as ATMPs. Thijs will present an analysis of current market trends in Quality Control (QC) automation, advancements in technology, and challenges in implementation.
Accelerating ATMP process development: in-line analytics and CFD simulations
Dr. ir. Marieke Klijn, Assistant Professor Data-Driven Bioprocess Development - TU Delft with Ramon van Valderen, PhD Candidate CFD modelling for ATMP scale-up - TU Delft
In this duo presentation we would like to showcase how we approach the implementation of novel analytical and computational techniques to accelerate bioprocess development. We are pursuing the implementation of in-line analytics, such as Raman spectroscopy, to gain more in-depth process understanding but also design scalable ATMP processes from a fundamental engineering perspective using advanced in-silico simulation techniques, such as computational fluid dynamics. For both types of technologies, we will dive into current research efforts to demonstrate the impact on process development and the challenges we have encountered along the way.
Digital-Twin assisted Biomanufacturing: From accelerated Process Development to automated Process Control
Dr. Mark Duerkop - Novasign GmbH with Evan Claes - Antleron
This presentation will highlight how smart experimental design combined with advanced process modeling techniques can reduce the number of lab experiments by up to 70% in the process development of ATMP manufacturing. These modeling techniques can be used within the Quality by Design (QbD) framework (see ICH Q8) to ensure that product quality is established from the outset through a comprehensive understanding and control of variables. Additionally, novel Design of Experiments (DoE) techniques are employed to systematically explore the relationships between multiple factors, optimizing processes efficiently. The presentation will also demonstrate how digital twins—virtual models of physical processes—facilitate easier scale-up, enable automated process control, and increase productivity while reducing costs. The latter will be illustrated with an industry-relevant case study by Antleron to underscore the practical benefits. A hybrid cell growth model is combined with a Cost-of-Goods model into a digital twin of a fixed-bed bioreactor expansion process, resulting in a reduction of both process development costs and time, while improving productivity.
How to set-up the GMP production of a cell therapy for Acute Myeloid Leukemia (AML) including automation in manufacturing, QC & release testing
Dr. Janet Hoogstraate - NorthX Biologics
Before innovative therapies can be put to the test in clinical studies the hurdle progressing to GMP manufacturing needs to be overcome. This requires the right expertise, takes time and can present substantial cost to the development program. Collaboration between innovation and manufacturing experts increases the probability of success to bring advanced therapies to patients. Early commitment to standardisation, automation and efficiency improvements can accelerate the progression of an idea to GMP manufacturing.
Implementation of automation in CAR T cell therapy production
Dr. Marc Kamp - Kite, a Gilead company
Abstract speaker will follow soon.
Novel Non-Viral DNA-based Gene Therapy vector for CAR T engineering in vivo
Jacek Lubelski PhD, MBA - NanoCell Therapeutics
Ex-vivo modification of immune cells to express Chimeric Antigen Receptor (CAR) has shown tremendous clinical and commercial success as a cancer treatment. Although widely adopted, ex-vivo CAR-T approaches are not without their challenges. Soaring production expenses, extended timelines, inherent toxicity risks and the operational intricacies of today’s conventional cell therapy treatment models calls for a next wave of improvements.
Here we present a novel cell-targeted lipid nanoparticle (tLNP) that can deliver both DNA and RNA to T cells. This new tLNP based vector consists of an LNP formulation containing transposon DNA (encoding for CAR), mRNA (encoding for transposase) and activating and targeting protein moieties. We will discuss the ability of this vector to activate resting primary T cells, thereby allowing their permanent modification with a DNA encoded CAR construct in vitro in the absence of exogenous activation resulting in the generation of fully functional CAR-T cells. In addition, the capacity of this non-viral vehicle to drive the generation of functional T-cells in vivo will be presented. We will demonstrate the generation of persistent CAR-T cells, tumour control and extended survival after tLNP treatment in a human PBMC engrafted NSG mouse model injected with a human B-cell leukaemia cell line. We believe that the CAR-T cells generated in vivo have a variety of advantages compared to currently employed ex-vivo manufacturing technologies.
Location of Dutch ATMP Summit
Corpus
Willem Enthovenstraat 1
2342 BH Oegstgeest
+31 (0) 23 563 50 16
(Progress Head Office)
Willem Einthovenstraat 1, 2342 BH Oegstgeest
This year's edition of the Dutch ATMP Summit takes place at Corpus Leiden
Dutch ATMP Summit 2025
With this ticket you will get access to the Dutch ATMP Summit on Wednesday March 12 2025 in Corpus Leiden. You can join all the talks of our speakers and meet your colleagues in the field during networking drinks. During the day there are refreshments.
Second ticket for half of the price!
Location of Dutch ATMP Summit
Corpus
Willem Enthovenstraat 1
2342 BH Oegstgeest
+31 (0) 23 563 50 16
(Progress Head Office)
About us
This summit is an initiative from Progress - Experts in Life Sciences
We work together with our clients, in order to obtain their goals. We work as a team to reach to the top. Progress is an independent consultancy company with customers in the pharmaceutical and biotechnology industries and in the healthcare sector. We provide project management, engineering & C&Q, CMC and Quality services.
About us
This summit is an initiative from Progress - Experts in Life Sciences
We work together with our clients, in order to obtain their goals. We work as a team to reach to the top. Progress is an independent consultancy company with customers in the pharmaceutical and biotechnology industries and in the healthcare sector. We operate internationally, project management, engineering & C&Q, CMC and Quality services.
